Your browser is no longer supported. Please, upgrade your browser.
Settings
BGMD BG Medicine, Inc. daily Stock Chart
BGMD [NASD]
BG Medicine, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own25.83% Shs Outstand11.37M Perf Week27.78%
Market Cap1.31M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.31M Perf Month64.29%
Income- PEG- EPS next Q- Inst Own7.10% Short Float7.58% Perf Quarter-4.17%
Sales1.57M P/S0.84 EPS this Y- Inst Trans-329.00% Short Ratio20.86 Perf Half Y-42.50%
Book/sh-0.18 P/B- EPS next Y- ROA- Target Price1.40 Perf Year-69.74%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.03 - 0.41 Perf YTD187.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.99% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low282.83% ATR0.01
Employees5 Current Ratio- Sales Q/Q-47.70% Oper. Margin- RSI (14)65.35 Volatility15.76% 19.15%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close0.12
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume30.21K Price0.11
Recom3.00 SMA2053.65% SMA5091.74% SMA200-23.47% Volume500 Change-0.13%
Apr-08-16 01:04PM  BG MEDICINE, INC. Financials
Apr-04-16 05:02PM  BG MEDICINE, INC. Files SEC form 10-K, Annual Report
Mar-31-16 05:06PM  BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
Feb-04-16 05:05PM  BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers +7.41%
Dec-23-15 07:58AM  BG MEDICINE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -27.59%
Dec-04-15 05:04PM  BG MEDICINE, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibit
Nov-30-15 07:50AM  BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits +6.56%
Nov-27-15 10:32AM  BG Medicine, Inc. Earnings Q3, 2015 +5.17%
Nov-23-15 04:25PM  BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Nov-20-15 05:02PM  BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Nov-17-15 08:02AM  BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statemen -14.93%
BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMerieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.